hline1.jpg (2302 bytes) PRESS ROOM hline1.jpg (2302 bytes)

Aurobindo gets EDQM approval for Flucloxacillin Sodium
US FDA grants tentative approval for Aurobindo's Sertraline
US FDA grants approval for Aurobindo's zidovudine
Aurobindo receives tentative approval for zidovudine tablet
Aurobindo receives second ANDA approval from US FDA for PEPFAR
Aurobindo receives the first ARV approval from US FDA
USFDA approval received for Unit VIII Facility
Aurobindo receives NABL approval for its Clinical Laboratory
Aurobindo records improved performance quarter on quarter
Successful USFDA Inspection of one more Unit
Obtains 3rd product approval from USFDA
Aurobindo in Forbes list
Best under a Billion - Asia's Rising Companies
Aurobindo receives US FDA approval for Citalopram
A robust generic product portfolio to unveil.
Aurobindo obtains two product approvals from US FDA
Records Rs.272 crore turnover in Q2
First product approval from US FDA received Foray into Regulated Market crosses first major milestone
Speech by the Chairman, Mr. P. V. Ramaprasad Reddy at the Annual General Meeting on 31st July 2004
Aurobindo posts Rs.2873 Millions sales and Rs.180 Million profit
Aurobindo net profit at Rs. 127 crs surges by 23%
UK MHRA (UK MCA) approval received for Unit 3
Subscription to preferential issue of equity shares
Aurobindo Q3 PAT grows by 68% Exports soar to 51% of sales
Aurobindo gets its first CoS approval from EDQM & files DMF for Citalopram
Aurobindo's Q2 Net Profit jumps to Rs.321.5 million, spurt by 57%
Preferential Issue of Equity Shares
Aurobindo net profit spurts by 52.75% in Q1
Aurobindo crosses the landmark Net Profit of Rs.100 crores
Aurobindo's demonstration of R&D leadership in cephalosporins
Aurobindo Pharma launches cefepime
Second quarter profit jumps  41.13%
Aurobindo implementing ERP package
First quarter profit jumps 34%
Aurobindo posts Net Profit of  Rs. 68.51 crores
Noted Cardiologist Dr. I. Satyamurthy joins Aurobindo Board
Aurobindo Pharma wins award for the best bulk drug company
Shares allotted to Templeton
Brazilian GMP certification received for the speciality generic formulations unit
Aurobindo Pharma acquires equity in Ranit Pharma
Mr. Lanka Srinivas inducted as Additional Director on Board of Aurobindo Pharma
Aurobindo Pharma launches Aztreonam for the first time in India  
Aurobindo Pharma & Citadel promote a joint venture  
Aurobindo Pharma welcomes excise duty exemption on anti-HIV drugs in budget
Aurobindo launches Cefactam (Cefoperazone plus Salbactam)
4th generation Cephalosporin – Cefpirome launched
Impressive Q3 performance 
Aurobindo shareholders approve Rs.125 crore Private Placement
Templeton to pick up equity
Aurobindo Pharma Board approves Rs. 125 crore private placement
Aurobindo Pharma launches two more antiretroviral products for HIV treatment
Restructuring on track
Aurobindo introduces two more drugs for treatment of Aids
Imunus Aurobindo launches two new anti-aids drugs
Aurobindo Pharma slashes prices of anti-aids drugs
Restructuring of Facilities
Income crosses Rs. 1000 crore land mark

www.aurobindo.com

Hyderabad, 9th September, 2004

COMPANY SCIENTISTS CONFERRED AWARDS

 
The Indian Drug Manufacturer’s Association and the Eighth Pharmaceutical Analysts Convention IDMA-APA PAC 2004 conferred prestigious awards on two of the research scientists at Aurobindo Pharma.
Dr. K. M. Thomas, Vice-President, Analytical Research & Development at the APL Research Center was conferred the “Eminent Pharmaceutical Analyst Award 2004” for specialisation in the field of Pharmaceutical Analysis. The citation referred to the sustained zeal, perseverance and ardour that characterize Dr. K. M. Thomas’s contribution as an analyst and researcher of repute, deserving of the highest recognition.
Dr. Satyanarayana Rao Penchala, Senior Scientist in the Analytical Research Department of the APL Research Center was conferred the “Young Pharmaceutical Analyst Award 2004” for the sterling contribution he has made in the field of Pharmaceutical Analysis. The citation endorsed his achievements at such a young age deserving the highest praise and compliments.
 
 

Top

________________________________________________________________